Johanna Adami is the director and head of health at VINNOVA, Sweden's innovation agency. She discusses Sweden's national innovation strategy and VINNOVA's role in funding research and innovation. VINNOVA aims to address grand challenges like health, the environment, and an aging population through collaborative projects bringing together researchers, industries, and other stakeholders both within Sweden and internationally. VINNOVA's health programs support personalized medicine, life sciences, and reforming healthcare to be more innovation-focused. The future roadmap involves stronger public-private partnerships and providing evidence of innovation outcomes.
HORIZON 2020 – a Strategic Element in Israel’s R&D Eco-System - Avi Hasson - ...ISERD Israel
Horizon 2020 Launch Event in Israel - Presentation of Avi Hasson, Chief Scientist of the Israeli Ministry of Economy and Chairman of ISERD's Steering Commitee
HORIZON 2020 – a Strategic Element in Israel’s R&D Eco-System - Avi Hasson - ...ISERD Israel
Horizon 2020 Launch Event in Israel - Presentation of Avi Hasson, Chief Scientist of the Israeli Ministry of Economy and Chairman of ISERD's Steering Commitee
Priorités thématiques et dimension internationale du projet H2020Pasteur_Tunis
Présentation du programme cadre H2020, par Aurélie Pancera, Expert PASRI, durant la journée de présentation du H2020, lors de la journée sur le programme H2020 organisée à l'Institut Pasteur de Tunis, le 20 septembre 2013
Presentatie Margriet Jansz (Programmamanager Technologiestichting STW) tijdens de Research Through Design – Inspiratie en Co-creatiedag op 12 februari 2015 in het Centraal Museum Utrecht.
Science, Technology and Innovation Outlook 2016 - EC/OECD Launch eventinnovationoecd
European Commission/OECD event - Launch of OECD Science, Technology and Innovation Outlook 2016
8 December 2016, EC Covent Garden, Auditorium Nowotny, Place Charles Rogier 16, 1210 Brussels.
The OECD's biennial publication of the Science, Technology and Industry Outlook "OECD STI Outlook" reviews key global trends in science, technology and innovation (STI) policies and performance in OECD countries and other major international economies. Through comparative analysis, it informs policy makers about recent and anticipated changes in global patterns of STI and their possible implications for national science and innovation policies.
Since 2015 the OECD and the European Commission pursue a joint approach in support of innovation policy through their "International Survey on Science, Technology and Innovation Policies". Unique in nature, coverage and scope, this common survey streamlines data collection and develops a coordinated approach in support of better informed innovation policy making. Its results feed into the country-based policy information in the STI Outlook.
EuroBioForum 2013 - Day 2 | Pelagiya DragomirovaEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# EARLY BIRD TALK #
The social media & web technology boost - intruder or trigger?
Pelagiya Dragomirova
Communications Advisor at Publimarket
=======================================
http://www.eurobioforum.eu
Priorités thématiques et dimension internationale du projet H2020Pasteur_Tunis
Présentation du programme cadre H2020, par Aurélie Pancera, Expert PASRI, durant la journée de présentation du H2020, lors de la journée sur le programme H2020 organisée à l'Institut Pasteur de Tunis, le 20 septembre 2013
Presentatie Margriet Jansz (Programmamanager Technologiestichting STW) tijdens de Research Through Design – Inspiratie en Co-creatiedag op 12 februari 2015 in het Centraal Museum Utrecht.
Science, Technology and Innovation Outlook 2016 - EC/OECD Launch eventinnovationoecd
European Commission/OECD event - Launch of OECD Science, Technology and Innovation Outlook 2016
8 December 2016, EC Covent Garden, Auditorium Nowotny, Place Charles Rogier 16, 1210 Brussels.
The OECD's biennial publication of the Science, Technology and Industry Outlook "OECD STI Outlook" reviews key global trends in science, technology and innovation (STI) policies and performance in OECD countries and other major international economies. Through comparative analysis, it informs policy makers about recent and anticipated changes in global patterns of STI and their possible implications for national science and innovation policies.
Since 2015 the OECD and the European Commission pursue a joint approach in support of innovation policy through their "International Survey on Science, Technology and Innovation Policies". Unique in nature, coverage and scope, this common survey streamlines data collection and develops a coordinated approach in support of better informed innovation policy making. Its results feed into the country-based policy information in the STI Outlook.
EuroBioForum 2013 - Day 2 | Pelagiya DragomirovaEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# EARLY BIRD TALK #
The social media & web technology boost - intruder or trigger?
Pelagiya Dragomirova
Communications Advisor at Publimarket
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Rotterdam Delta, The Netherlands:
What’s keeping medicine from becoming personalised?
Dr Menno Kok,
Advisor Research Strategies Erasmus MC and sector manager Medical Delta
=======================================
http://www.eurobioforum.eu
Presentation "Innovating for Health and Well-being" at WHO International Healthy Cities conference, Athens, Greece, 25/OCT/2014, Arto Holopainen, Development Director, Kuopio Innovation Ltd.
The EIT Health Alumni Network is a cross-sectoral community that connects alumni of EIT Health’s education, innovation and business acceleration activities. This network brings together entrepreneurs, students, and healthcare professionals who share a common vision for creating positive societal impact through innovation and entrepreneurship.
Sweden - National System of Innovation SummaryTrevor Roald
This presentation summarizes the national system of innovation for Sweden. The presentation was prepared for the Simon Fraser University BUS 750 course. This course was part of the Management of Technology MBA program for 2015.
ISPOR Eupati meeting - Dr Derick Mitchell - November 2017ipposi
The IPPOSI CEO delivered a presentation at the international HTA conference about IPPOSI's role in EUPATI and the importance of engaging patients in HTA and health innovation R&D.
Horizon 2020: Funding opportunities for academic & business research partners...Iraklis Agiovlasitis
A guide for funding opportunities through Horizon 2020, targeted at academic & business research partnerships in the medical imaging sector.
Presented on the PSMR 2014 Conferece / 3rd Conference on PET/MR and SPECT/MR, 19th -21st May 2014, at Kos, Greece.
EuroBioForum 2013 - Day 1 | Wolfgang EberleEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Belgium
Working across disciplines for our health benefit - From successful strategies for biotech and nanotech to Nanotech for Health in Flanders
Wolfgang Eberle
Funded Program Manager Life Science Technologies Imec
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 2 | Rachael RitchieEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Genome British Colombia, Canada:
Regional Perspectives on Personalized Medicine in British Columbia, Canada
Dr Rachael Ritchie
Director Business Development Genome British Colombia
=======================================
http://www.eurobioforum.eu
The heart of life sciences full reportEuroBioForum
This report invites you to read more about why Denmark is a unique laboratory for healthcare and welfare
technology, and why Denmark is an excellent place to do business.
EuroBioForum 2013 - Day 2 | Jami TaylorEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# KEYNOTE PRESENTATION #
Personalised medicine education & training
Macro challenges and the path forward
Jami Taylor
Senior Director, Global Access Policy at Janssen, the Pharmaceutical Companies of Johnson & Johnson
Vice-chair of the Education Committee of EPEMED
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 2 | Frank MolinaEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
EuroBioMed, France:
Private-public collaborations to boost open innovation
Dr Franck Molina
President of EDCA, Chair of diagnosis group of Eurobiomed
Director of Sysdiag
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 2 | Mark PoznanskyEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Ontario Genomics Institute, Canada:
Innovative Research, Innovative Translation
Dr Mark Poznansky
President and CEO Ontario Genomics Institute
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 2 | Marc LapageEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Genome Quebec, Canada:
Personalised medicine – Reaching the patient?
Marc LePage
President and CEO Genome Quebec
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 1 | Etienne RicherEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Canada:
Personalised Medicine: A Canadian Collaborative Perspective'
Dr Étienne Richer, Assistant Director at CIHR Institute of Genetics
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 1 | Pierre MeulienEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Canada:
Genomics and personalised health in Canada
Dr Pierre Meulien, President and CEO at Genome Canada
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 1 | Oyvind MelienEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Norway:
Personalised medicine in Norway
Dr Øyvind Melien
Senior Advisor at Norwegian Directorate of Health
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 1 | Anne EckhardtEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Switzerland:
Personalised medicine in Switzerland under a societal perspective
Dr Anne Eckhard
Consultant on behalf of the Swiss Academies of Arts and Sciences
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 1 | Karin EffertzEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Germany:
Personalized Medicine at the German Federal Ministry of Education and Research (BMBF)
Karin Effertz
Scientific Officer at Federal Ministry for Education and Research
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 1 | Sergey SuchkovEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Russia:
Introduction into PPPM as a new paradigm of public health care service and an example of the ready-to-use Clinical Model in the Area of Medicine
Sergey Suchkov
Professor in Medicine and Immunology at Moscow State Medical & Dental University & I.M. Sechenov Moscow Medical Academy
=======================================
http://www.eurobioforum.eu
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
EuroBioForum2014_speaker_Adami
1. Johanna Adami
Professor and Director and Head of Health
Division VINNOVA , Swedish Government
Agency for Innovation System, Sweden
National perspective Sweden
2. Challenge driven innovations for future health – a roadmap for success
Johanna Adami, MD MPH PhD Professor
Director and Head of Health Division
3. Sweden – A small, open economy
•Sweden is sparsely populated. 9,7 million inhabitants…
•…but large: Surface area 450,000 km2.
•Exports: 46 percent of GDP - 30 percent services and 70 percent goods
•Foreign owned enterprises employ more than 630,000 persons. Around 13 percent of total employment.
•Foreign owned enterprises perform around 38 percent of the business R&D in Sweden.
4. Total R&D expenditure in relation to GDP, 2011
Source: OECD, MSTI 2014
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
Norway
Canada
United Kingdom
China
Netherlands
Singapore
Australia
Belgium
France
Estonia
Slovenia
Iceland
USA
Austria
Switzerland (2008)
Germany
Denmark
Taiwan
Japan
Sweden
Finland
Israel
Korea
Percent of GDP
Business enterprise
Higher education
Government sector
Other organisations
5. Sweden ranks high in innovation and competitiveness
Innovation Union Scoreboard 2014
Global Competitiveness Index 2013/2014
Switzerland
Switzerland
Sweden
Singapore
Denmark
Finland
Germany
Germany
Finland
United States
Luxembourg
Sweden
Netherlands
Hong Kong
Belgium
Netherlands
United Kingdom
Japan
Ireland
United Kingdom
Source: Innovation Union Scoreboard 2014 and World Economic Forum, Global Competitiveness Report 2013/14.
7. The Challenge ahead
Slide 7
How to stay competetive long term?
•Continued creation of high productive jobs – Attract and retain R&D activities
•Build on existing strengths
•Embrace globalization
•Removing barriers – Innovation policy crucial
8. National Innovation strategy
Bild 8
•2020 time horizon
•Broad definition of innovation
•Focus on societal challenges
•Holistic approach to innovation and innovation support
•Innovation as a driver of national attractiveness and competitiveness
10. VINNOVA in brief
•VINNOVA – the Swedish Governmental Agency for Innovation responding to the Ministry of Enterprise
•About 200 people work at VINNOVA’s offices in Stockholm, Brussels and Silicon Valley
•Annual budget of 300 million Euros invested in innovation projects in all sectors in society.
11. Three roles
Funding Research & Innovation
National EU Contact Agency
Expert Agency
13. Implementation!
Strategic Innovation Areas
Implementation!
EU-coordination secretariat
Implementation!
Develop the Knowledge triangle approach at universities
VINNOVA focus
14. 2014-09-26
Bild 14
Key principles of operation
•for increased impacts of research
•broad innovation perspective; goods, services, processes, etc.
•confidence in the actors to define their own development strategies
•we develop and test new forms for investments
•we develop and strengthen beneficial international cooperation
15. Key features of VINNOVA programs
Funding through grants
Main funding mechanism at VINNOVA
Program period of 3-10 years
One or several open ”call-for-proposals”
Project requirements:
•Industry-relevant
•Industry-academy-research institute- public sector partners
•Co-funding, VINNOVA max. 50%
•1-10 years projects
•Level of funding appr. € 0.3 to 10 M per project
16. International programs
Bild 16
North and South America
USA: Road/Vehicle Safety Innovation program
Brazil: Innovation program
Europe
EU FP7, ERAnets, INCOnets, AAL, Artemis, Eniac, EUREKA, COST, Eurostars, TAFTIE, BSR
Nordic region
ICT, e-Gov’t, Transport policy
Asia
India Life sci.y/health, ICT
Japan Multidisciplinary Bio (JST to 2013), Network projects (JSPS)
China ICT (concluded, Material science, Eco-innovation
Other cooperations
South Korea, Canada, Israel: EUREKA/Eurostars
Active government agreement in S&T and/or innovation
Formalized cooperation with budget
Bilateral program
Eureka/Eurostars
17. We are facing a number of grand challenges
Environment
Health
Ageing
population
Globalization
18. To address these challenges
You need to
•Bring world class research together
•Combine skills from many sectors
•Apply known technologies into new applications
•Utilize the best expertise from all over the world
Bild 18
opportunities
20. Strategy for Health Innovation
Bild 20
Global re-structuring in lifescience
Global health challenges: lifestyle, demographic changes, etc
Health care challenges; cost vs quality – innovation potential
Weak links between high-quality research and needs-driven innovation
Business meets global health needs
Globally attractive innovation system
Health care - partner in innovation
VISION
CHALLENGES
21. Ongoing programs in health
Bild 21
Test beds
International collaborations
Public procurement
Collaboration
Business, Public sector & Academia
Innovation hubs
Incubators
European collaboration programs
R&D&I Projects
22. Personlized medicine – some results
VINN Cardio – biomarkers for individualized treament for cardiovascular disease
Create Health – individualized cancer treatment
Tailored Leukapheresis for treatment of immune mediated inflammatory diseases
Endemic diseases: To make Sweden one of the world's leading ecosystems for life science focusing on diabetes and other endemic diseases.
2014-09-26
Bild 22
23. ECOSYSTEM for health/lifescience/health care/
INDUSTRY
PATIENT
HEALTH CARE DELIVERY
Payers/fiscal intermediaries
Medical technology
Pharma- ceuticals
Diagnostics
Public
Private
Professional groups
AUTHORITIES
Regulating
RESEARCH/
EDUCATION
Regulatory
Industry- organisations
SME
Large companiess
24. Roadmap for the future
Reform health care –public sector should be a partner in innovation
Stimulate valuedriven innovation for all
Provide evidence for the outcomes
Work closely with regulatory agencies
Promote Incentives such as reimbursement models, public procurement etc.
Support databases/registries
Public Private Partnership
Promote active partnership with relevant stakeholders
2014-09-26
Bild 24
25. Collaboration is the basis for all VINNOVA funding
2014-09-26
Bild 25
X
Sectors
Research fields
Technologies
Types of Actors
Nations